Addington, D, Addington, J and Schissel, B (1990) A depression rating scale for schizophrenics. Schizophrenia Research 3, 247–251.
Adolphs, R (2009) The social brain: neural basis of social knowledge. Annual Review of Psychology 60, 693–716.
Andreasen, N (1982) The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: The University of Iowa.
Bakermans-Kranenburg, M and Van Ijzendoorn, M (2013) Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Translational Psychiatry 3, e258.
Baron-Cohen, S, Wheelwright, S, Hill, J, Raste, Y and Plumb, I (2001) The “reading the mind in the eyes” test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. The Journal of Child Psychology and Psychiatry and Allied Disciplines 42, 241–251.
Bartz, JA, Zaki, J, Bolger, N and Ochsner, KN (2011) Social effects of oxytocin in humans: context and person matter. Trends in Cognitive Sciences 15, 301–309.
Baumgartner, T, Heinrichs, M, Vonlanthen, A, Fischbacher, U and Fehr, E (2008) Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58, 639–650.
Beckmann, H, Lang, RE and Gattaz, WF (1985) Vasopressin – oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 10, 187–191.
Bethlehem, RA, van Honk, J, Auyeung, B and Baron-Cohen, S (2013) Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. Psychoneuroendocrinology 38, 962–974.
Birchwood, M, Smith, J, Cochrane, R, Wetton, S and Copestake, S (1990) The social functioning scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. The British Journal of Psychiatry 157, 853–859.
Bradley, ER and Woolley, JD (2017) Oxytocin effects in schizophrenia: reconciling mixed findings and moving forward. Neuroscience & Biobehavioral Reviews 80, 36–56.
Brambilla, M, Cotelli, M, Manenti, R, Dagani, J, Sisti, D, Rocchi, M, Balestrieri, M, Pini, S, Raimondi, S and Saviotti, FM (2016) Oxytocin to modulate emotional processing in schizophrenia: a randomized, double-blind, cross-over clinical trial. European Neuropsychopharmacology 26, 1619–1628.
Bürkner, P-C, Williams, DR, Simmons, TC and Woolley, JD (2017) Intranasal oxytocin may improve high-level social cognition in schizophrenia, but not social cognition or neurocognition in general: a multilevel Bayesian meta-analysis. Schizophrenia Bulletin 43, 1291–1303.
Cacciotti-Saija, C, Langdon, R, Ward, PB, Hickie, IB, Scott, EM, Naismith, SL, Moore, L, Alvares, GA, Redoblado Hodge, MA and Guastella, AJ (2015) A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophrenia Bulletin 41, 483–493.
Churchland, PS and Winkielman, P (2012) Modulating social behavior with oxytocin: how does it work? What does it mean?. Hormones and Behavior 61, 392–399.
Davis, MC, Lee, J, Horan, WP, Clarke, AD, McGee, MR, Green, MF and Marder, SR (2013) Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophrenia Research 147, 393–397.
Davis, MC, Green, MF, Lee, J, Horan, WP, Senturk, D, Clarke, AD and Marder, SR (2014) Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 39, 2070–2077.
Domes, G, Heinrichs, M, Michel, A, Berger, C and Herpertz, SC (2007) Oxytocin improves “mind-reading” in humans. Biological Psychiatry 61, 731–733.
First, MB, Spitzer, RL, Gibbon, M and Williams, JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis 1 Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.
Fischer-Shofty, M, Brüne, M, Ebert, A, Shefet, D, Levkovitz, Y and Shamay-Tsoory, SG (2013) Improving social perception in schizophrenia: the role of oxytocin. Schizophrenia Research 146, 357–362.
Freeman, SM and Young, LJ (2016) Comparative perspectives on oxytocin and vasopressin receptor research in rodents and primates: translational implications. Journal of Neuroendocrinology 28.
Gibson, CM, Penn, DL, Smedley, KL, Leserman, J, Elliott, T and Pedersen, CA (2014) A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophrenia Research 156, 261–265.
Goldman, M, Marlow-O'Connor, M, Torres, I and Carter, CS (2008) Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophrenia Research 98, 247–255.
Goldman, MB, Gomes, AM, Carter, CS and Lee, R (2011) Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (Berl) 216, 101–110.
Granholm, EL, McQuaid, JR and Holden, JL (2016) Cognitive-behavioral Social Skills Training for Schizophrenia: A Practical Treatment Guide. New York: Guilford Publications.
Green, MF, Penn, DL, Bentall, R, Carpenter, WT, Gaebel, W, Gur, RC, Kring, AM, Park, S, Silverstein, SM and Heinssen, R (2008) Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophrenia Bulletin 34, 1211–1220.
Guastella, AJ and MacLeod, C (2012) A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Hormones and Behavior 61, 410–418.
Guastella, AJ, Mitchell, PB and Dadds, MR (2008 a) Oxytocin increases gaze to the eye region of human faces. Biological Psychiatry 63, 3–5.
Guastella, AJ, Mitchell, PB and Mathews, F (2008 b) Oxytocin enhances the encoding of positive social memories in humans. Biological Psychiatry 64, 256–258.
Guastella, AJ, Howard, AL, Dadds, MR, Mitchell, P and Carson, DS (2009) A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 34, 917–923.
Guastella, AJ, Ward, PB, Hickie, IB, Shahrestani, S, Hodge, MAR, Scott, EM and Langdon, R (2015) A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia. Schizophrenia Research 168, 628–633.
Guy, W (1976) ECDEU assessment Manual for Psychopharmacology. US Department of Health, and Welfare, pp. 534–537.
Horan, WP, Kern, RS, Shokat-Fadai, K, Sergi, MJ, Wynn, JK and Green, MF (2009) Social cognitive skills training in schizophrenia: an initial efficacy study of stabilized outpatients. Schizophrenia Research 107, 47–54.
Horta de Macedo, LRH, Zuardi, AW, Machado-de-Sousa, JP, Chagas, MHN and Hallak, JE (2014) Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task. Psychiatry Research 220, 125–128.
Keech, B, Crowe, S and Hocking, DR (2018) Intranasal oxytocin, social cognition and neurodevelopmental disorders: a meta-analysis. Psychoneuroendocrinology 87, 9–19.
Kern, RS, Penn, DL, Lee, J, Horan, WP, Reise, SP, Ochsner, KN, Marder, SR and Green, MF (2013) Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties. Schizophrenia Bulletin 39, 1201–1210.
Kosfeld, M, Heinrichs, M, Zak, PJ, Fischbacher, U and Fehr, E (2005) Oxytocin increases trust in humans. Nature 435, 673–676.
Lee, MR, Wehring, HJ, McMahon, RP, Liu, F, Linthicum, J, Verbalis, JG, Buchanan, RW, Strauss, GP, Rubin, LH and Kelly, DL (2016) Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia. Schizophrenia Research 172, 165–168.
Leng, G and Ludwig, M (2016) Intranasal oxytocin: myths and delusions. Biological Psychiatry 79, 243–250.
Loughland, CM, Williams, LM and Gordon, E (2002) Visual scanpaths to positive and negative facial emotions in an outpatient schizophrenia sample. Schizophrenia Research 55, 159–170.
Luminet, O, Grynberg, D, Ruzette, N and Mikolajczak, M (2011) Personality-dependent effects of oxytocin: greater social benefits for high alexithymia scorers. Biological Psychology 87, 401–406.
Mancuso, F, Horan, WP, Kern, RS and Green, MF (2011) Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. Schizophrenia Research 125, 143–151.
Manning, M, Misicka, A, Olma, A, Bankowski, K, Stoev, S, Chini, B, Durroux, T, Mouillac, B, Corbani, M and Guillon, G (2012) Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. Journal of Neuroendocrinology 24, 609–628.
Marsh, AA, Henry, HY, Pine, DS and Blair, R (2010) Oxytocin improves specific recognition of positive facial expressions. Psychopharmacology 209, 225–232.
Matsumoto, D and Ekman, P (1995) Japanese and Caucasian Facial Expressions of Emotion (JACFEE) and Neutral Faces (JACNeuF).
Parker, KJ, Oztan, O, Libove, RA, Sumiyoshi, RD, Jackson, LP, Karhson, DS, Summers, JE, Hinman, KE, Motonaga, KS, Phillips, JM and Carson, DS (2017) Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proceedings of the National Academy of Sciences 114, 8119–8124.
Pedersen, CA, Gibson, CM, Rau, SW, Salimi, K, Smedley, KL, Casey, RL, Leserman, J, Jarskog, LF and Penn, DL (2011) Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophrenia Research 132, 50–53.
Penn, D and Combs, D (2000) Modification of affect perception deficits in schizophrenia. Schizophrenia Research 46, 217–229.
Penn, DL, Roberts, DL, Combs, D and Sterne, A (2007) Best practices: the development of the social cognition and interaction training program for schizophrenia spectrum disorders. Psychiatric Services 58, 449–451.
Pinkham, AE, Penn, DL, Perkins, DO and Lieberman, J (2003) Implications for the neural basis of social cognition for the study of schizophrenia. American Journal of Psychiatry 160, 815–824.
Quintana, DS (2018) Revisiting non-significant effects of intranasal oxytocin using equivalence testing. Psychoneuroendocrinology 87, 127–130.
Quintana, DS and Woolley, JD (2016) Intranasal oxytocin mechanisms can be better understood, but its effects on social cognition and behavior are not to be sniffed at. Biological Psychiatry 79, e49–e50.
Roberts, DL, Penn, DL and Combs, DR (2015) Social Cognition and Interaction Training (SCIT): Group Psychotherapy for Schizophrenia and Other Psychotic Disorders, Clinician Guide. New York: Oxford University Press.
Rubin, LH, Carter, CS, Drogos, L, Pournajafi-Nazarloo, H, Sweeney, JA and Maki, PM (2010) Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophrenia Research 124, 13–21.
Rubin, LH, Carter, CS, Drogos, L, Jamadar, R, Pournajafi-Nazarloo, H, Sweeney, JA and Maki, PM (2011) Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia. Schizophrenia Research 130, 266–270.
Rubin, LH, Carter, CS, Bishop, JR, Pournajafi-Nazarloo, H, Harris, MS, Hill, SK, Reilly, JL and Sweeney, JA (2013) Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophrenia Research 146, 138–143.
Rubin, LH, Carter, CS, Bishop, JR, Pournajafi-Nazarloo, H, Drogos, LL, Hill, SK, Ruocco, AC, Keedy, SK, Reilly, JL, Keshavan, MS, Pearlson, GD, Tamminga, CA, Gershon, ES and Sweeney, JA (2014) Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophrenia Bulletin 40, 1374–1384.
Savaskan, E, Ehrhardt, R, Schulz, A, Walter, M and Schächinger, H (2008) Post-learning intranasal oxytocin modulates human memory for facial identity. Psychoneuroendocrinology 33, 368–374.
Shin, NY, Park, HY, Jung, WH, Park, JW, Yun, J-Y, Jang, JH, Kim, SN, Han, HJ, Kim, S-Y and Kang, D-H (2015) Effects of oxytocin on neural response to facial expressions in patients with schizophrenia. Neuropsychopharmacology 40, 1919–1927.
Strauss, GP, Keller, WR, Koenig, JI, Gold, JM, Frost, KH and Buchanan, RW (2015 a) Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. Schizophrenia Research 162, 47–51.
Strauss, GP, Keller, WR, Koenig, JI, Gold, JM, Ossenfort, KL and Buchanan, RW (2015 b) Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia. Schizophrenia Research 162, 57–61.
Strauss, GP, Keller, WR, Koenig, JI, Sullivan, SK, Gold, JM and Buchanan, RW (2015 c) Endogenous oxytocin levels are associated with the perception of emotion in dynamic body expressions in schizophrenia. Schizophrenia Research 162, 52–56.
Van't Wout, M and Sanfey, AG (2008) Friend or foe: the effect of implicit trustworthiness judgments in social decision-making. Cognition 108, 796–803.
Ventura, J, Lukoff, D, Nuechterlein, K, Liberman, R, Green, M and Shaner, A (1993) Brief Psychiatric Rating Scale (Expanded, Version 4.0). Los Angeles: UCLA Department of Psychiatry and Behavioural Sciences. Clinical Research Center for Schizophrenia and Psychiatric Rehabilitation.
Williams, LM, Loughland, CM, Green, MJ, Harris, AW and Gordon, E (2003) Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. Haloperidol. Psychiatry Research 120, 13–27.
Woolley, JD, Chuang, B, Lam, O, Lai, W, O'Donovan, A, Rankin, KP, Mathalon, DH and Vinogradov, S (2014) Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology 47, 116–125.
Woolley, J, Chuang, B, Fussell, C, Scherer, S, Biagianti, B, Fulford, D, Mathalon, D and Vinogradov, S (2017) Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls. Psychological Medicine 47, 1311–1322.
Zaki, J, Bolger, N and Ochsner, K (2008) It takes two: the interpersonal nature of empathic accuracy. Psychological Science 19, 399–404.